ArticleBJPsych open2024

Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia.

Dan Siskind et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.